pSivida Corp (PSDV) Downgraded by Zacks Investment Research to “Underperform”
Equities research analysts at Zacks Investment Research downgraded shares of pSivida Corp (NASDAQ: PSDV) from a “neutral” rating to an “underperform” rating in a research note to investors on Friday.
pSivida Corp. develops drug delivery products that are administered by implantation, injection or insertion. Once administered, a drug is released on a controlled and level basis for months or years. The Company has two core technology systems, Durasert and BioSilicon. pSivida Corp. has one product candidate for chronic eye disease that has been given Priority Review by the United States Food and Drug Administration (FDA). It has a collaboration with Pfizer, Inc. (Pfizer) to develop additional ophthalmic products. Iluvien, the product candidiate with Priority Review, is designed to provide sustained release treatment for Diabetic Macula Edema (DME). Iluvien is licensed to Alimera Sciences, Inc (Alimera), which is completing fully-recruited Phase III clinical trials.
Shares of pSivida Corp (NASDAQ: PSDV) traded down 5.64% during mid-day trading on Wednesday, hitting $3.85. pSivida Corp has a 52 week low of $3.08 and a 52 week high of $7.22. The stock’s 50-day moving average is $4.74 and its 200-day moving average is $4.71. On average, analysts predict that pSivida Corp will post $-0.16 EPS next quarter. The company has a market cap of $71.3 million and a price-to-earnings ratio of 10.77.
For more information about Zacks Investment Research‘s equity research offerings, visit Zacks.com.
Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts’ upgrades, analysts’ downgrades and analysts’ price target changes for each day. Click Here to register.
americanbankingnews.com |
